However, because of its antagonist decoy receptor, TRID, which is expressed in normal cells and blocks the apoptotic signaling of DR4/DR5 but is not well expressed in cancer cells [29], [30], [31], the apoptotic signaling of TRAIL is decreased in normal cells but not in tumor cells [23], [24], [32], [33], While the TRAIL-related therapeutic approach has been shown to control the growth of certain types of cancer [31], [34], it has been ineffective for pancreatic cancer [35]. Here, TNFSF10 is linked to familial pancreatic carcinoma.